Characterization of COVID-19 cases in the early phase (March to July 2020) of the pandemic in Kenya.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
30 Dec 2022
Historique:
entrez: 30 12 2022
pubmed: 31 12 2022
medline: 3 1 2023
Statut: epublish

Résumé

Kenya detected the first case of COVID-19 on March 13, 2020, and as of July 30, 2020, 17 975 cases with 285 deaths (case fatality rate (CFR) = 1.6%) had been reported. This study described the cases during the early phase of the pandemic to provide information for monitoring and response planning in the local context. We reviewed COVID-19 case records from isolation centres while considering national representation and the WHO sampling guideline for clinical characterization of the COVID-19 pandemic within a country. Socio-demographic, clinical, and exposure data were summarized using median and mean for continuous variables and proportions for categorical variables. We assigned exposure variables to socio-demographics, exposure, and contact data, while the clinical spectrum was assigned outcome variables and their associations were assessed. A total of 2796 case records were reviewed including 2049 (73.3%) male, 852 (30.5%) aged 30-39 years, 2730 (97.6%) Kenyans, 636 (22.7%) transporters, and 743 (26.6%) residents of Nairobi City County. Up to 609 (21.8%) cases had underlying medical conditions, including hypertension (n = 285 (46.8%)), diabetes (n = 211 (34.6%)), and multiple conditions (n = 129 (21.2%)). Out of 1893 (67.7%) cases with likely sources of exposure, 601 (31.8%) were due to international travel. There were 2340 contacts listed for 577 (20.6%) cases, with 632 contacts (27.0%) being traced. The odds of developing COVID-19 symptoms were higher among case who were aged above 60 years (odds ratio (OR) = 1.99, P = 0.007) or had underlying conditions (OR = 2.73, P < 0.001) and lower among transport sector employees (OR = 0.31, P < 0.001). The odds of developing severe COVID-19 disease were higher among cases who had underlying medical conditions (OR = 1.56, P < 0.001) and lower among cases exposed through community gatherings (OR = 0.27, P < 0.001). The odds of survival of cases from COVID-19 disease were higher among transport sector employees (OR = 3.35, P = 0.004); but lower among cases who were aged ≥60 years (OR = 0.58, P = 0.034) and those with underlying conditions (OR = 0.58, P = 0.025). The early phase of the COVID-19 pandemic demonstrated a need to target the elderly and comorbid cases with prevention and control strategies while closely monitoring asymptomatic cases.

Sections du résumé

Background UNASSIGNED
Kenya detected the first case of COVID-19 on March 13, 2020, and as of July 30, 2020, 17 975 cases with 285 deaths (case fatality rate (CFR) = 1.6%) had been reported. This study described the cases during the early phase of the pandemic to provide information for monitoring and response planning in the local context.
Methods UNASSIGNED
We reviewed COVID-19 case records from isolation centres while considering national representation and the WHO sampling guideline for clinical characterization of the COVID-19 pandemic within a country. Socio-demographic, clinical, and exposure data were summarized using median and mean for continuous variables and proportions for categorical variables. We assigned exposure variables to socio-demographics, exposure, and contact data, while the clinical spectrum was assigned outcome variables and their associations were assessed.
Results UNASSIGNED
A total of 2796 case records were reviewed including 2049 (73.3%) male, 852 (30.5%) aged 30-39 years, 2730 (97.6%) Kenyans, 636 (22.7%) transporters, and 743 (26.6%) residents of Nairobi City County. Up to 609 (21.8%) cases had underlying medical conditions, including hypertension (n = 285 (46.8%)), diabetes (n = 211 (34.6%)), and multiple conditions (n = 129 (21.2%)). Out of 1893 (67.7%) cases with likely sources of exposure, 601 (31.8%) were due to international travel. There were 2340 contacts listed for 577 (20.6%) cases, with 632 contacts (27.0%) being traced. The odds of developing COVID-19 symptoms were higher among case who were aged above 60 years (odds ratio (OR) = 1.99, P = 0.007) or had underlying conditions (OR = 2.73, P < 0.001) and lower among transport sector employees (OR = 0.31, P < 0.001). The odds of developing severe COVID-19 disease were higher among cases who had underlying medical conditions (OR = 1.56, P < 0.001) and lower among cases exposed through community gatherings (OR = 0.27, P < 0.001). The odds of survival of cases from COVID-19 disease were higher among transport sector employees (OR = 3.35, P = 0.004); but lower among cases who were aged ≥60 years (OR = 0.58, P = 0.034) and those with underlying conditions (OR = 0.58, P = 0.025).
Conclusion UNASSIGNED
The early phase of the COVID-19 pandemic demonstrated a need to target the elderly and comorbid cases with prevention and control strategies while closely monitoring asymptomatic cases.

Identifiants

pubmed: 36583253
doi: 10.7189/jogh.12.15001
pmc: PMC9801068
doi:

Types de publication

Case Reports Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15001

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2022 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.

Références

J Nurs Manag. 2020 Jul;28(5):1002-1009
pubmed: 32255222
BMJ Open. 2021 Jun 28;11(6):e041240
pubmed: 34183334
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Trop Med Int Health. 2021 Jan;26(1):2-13
pubmed: 33012053
SN Compr Clin Med. 2020;2(8):1069-1076
pubmed: 32838147
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33571106
Emerg Infect Dis. 2020 May;26(5):1052-1054
pubmed: 32091386
Elife. 2020 Feb 24;9:
pubmed: 32091395
Ann Intensive Care. 2020 Mar 18;10(1):33
pubmed: 32189136
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Influenza Other Respir Viruses. 2020 Jul;14(4):474-475
pubmed: 32246886
Eur J Clin Invest. 2020 Oct;50(10):e13378
pubmed: 32860457
J Med Virol. 2020 Nov;92(11):2821-2829
pubmed: 32543710
Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Dec;47(12):1095-9
pubmed: 24529266
One Health. 2020 Dec;10:100166
pubmed: 32904481
Lancet Glob Health. 2020 Jun;8(6):e738-e739
pubmed: 32389194
N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
Br J Pharmacol. 2020 Oct;177(19):4375-4385
pubmed: 32698249
Psychol Trauma. 2020 Aug;12(S1):S55-S57
pubmed: 32551762
J Infect Chemother. 2021 Jan;27(1):70-75
pubmed: 32950393
Proc Biol Sci. 2003 Dec 22;270(1533):2565-71
pubmed: 14728778
Clin Neuropsychiatry. 2020 Apr;17(2):63-64
pubmed: 34908969
Cochrane Database Syst Rev. 2021 Feb 23;2:CD013665
pubmed: 33620086
Front Public Health. 2021 Jan 15;8:582932
pubmed: 33520910
Eur J Public Health. 2002 Mar;12(1):22-8
pubmed: 11968516
Appl Health Econ Health Policy. 2020 Jun;18(3):333-334
pubmed: 32266703
Clin Microbiol Infect. 2020 Nov;26(11):1450-1452
pubmed: 32777361
J Intern Med. 2020 Oct;288(4):469-476
pubmed: 32498135
Clin Infect Dis. 2010 Mar 15;50(6):826-32
pubmed: 20156059
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa271
pubmed: 33117855
Epidemiol Health. 2020;42:e2020046
pubmed: 32580531
JAMA. 2020 Sep 8;324(10):935-936
pubmed: 32897351
SN Compr Clin Med. 2020;2(7):874-876
pubmed: 32838138
MMWR Suppl. 2004 Sep 24;53:5-11
pubmed: 15714620
Transpl Int. 2017 Jan;30(1):6-10
pubmed: 27896874
Int J Infect Dis. 2021 Jan;102:226-232
pubmed: 33075534
BMJ Open. 2020 Oct 6;10(10):e040129
pubmed: 33028563
JAMA Pediatr. 2021 Aug 1;175(8):817-826
pubmed: 33885740
Infect Dis Poverty. 2020 Jul 8;9(1):85
pubmed: 32641121
PLoS One. 2020 Nov 18;15(11):e0241541
pubmed: 33206661

Auteurs

Philip Ngere (P)

Department of Disease Surveillance and Epidemic Response, Ministry of Health, Kenya.
Washington State University, Global Health, Kenya.

Joyce Onsongo (J)

World Health Organization, Nairobi Kenya.

Daniel Langat (D)

Department of Disease Surveillance and Epidemic Response, Ministry of Health, Kenya.

Elizabeth Nzioka (E)

Public Health Emergency Operation Centre, Ministry of Health, Kenya.

Faith Mudachi (F)

Department of Promotive and Preventive Health, Ministry of Health, Kenya.

Samuel Kadivane (S)

Department of Disease Surveillance and Epidemic Response, Ministry of Health, Kenya.

Bernard Chege (B)

Public Health Emergency Operation Centre, Ministry of Health, Kenya.

Elvis Kirui (E)

National Public Health Laboratory Services, Ministry of Health, Kenya.

Ian Were (I)

Office of the Director General, Ministry of Health, Kenya.

Stephen Mutiso (S)

Department of Promotive and Preventive Health, Ministry of Health, Kenya.

Amos Kibisu (A)

Public Health Emergency Operation Centre, Ministry of Health, Kenya.

Josephine Ihahi (J)

Public Health Emergency Operation Centre, Ministry of Health, Kenya.

Gladys Mutethya (G)

Public Health Emergency Operation Centre, Ministry of Health, Kenya.

Trufosa Mochache (T)

World Health Organization, Nairobi Kenya.

Peter Lokamar (P)

National Public Health Laboratory Services, Ministry of Health, Kenya.

Waqo Boru (W)

Field Epidemiology and Laboratory Training Program, Ministry of Health, Kenya.

Lyndah Makayotto (L)

Department of Disease Surveillance and Epidemic Response, Ministry of Health, Kenya.

Emmanuel Okunga (E)

Department of Disease Surveillance and Epidemic Response, Ministry of Health, Kenya.

Nollascus Ganda (N)

World Health Organization, Nairobi Kenya.

Adam Haji (A)

World Health Organization, Nairobi Kenya.

Carolyne Gathenji (C)

World Health Organization, Nairobi Kenya.

Winfred Kariuki (W)

World Health Organization, Nairobi Kenya.

Eric Osoro (E)

Washington State University, Global Health, Kenya.

Kadondi Kasera (K)

Public Health Emergency Operation Centre, Ministry of Health, Kenya.

Francis Kuria (F)

Directorate of Public Health, Ministry of Health, Kenya.

Rashid Aman (R)

Cabinet Administrative Secretary, Ministry of Health, Kenya.

Juliet Nabyonga (J)

World Health Organization, Nairobi Kenya.

Patrick Amoth (P)

Office of the Director General, Ministry of Health, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH